{
}
UBS has downgraded Novartis to Neutral from Buy, citing concerns over patent expirations and a limited pipeline, with EBIT growth expected to decline significantly in 2025. In contrast, Roche and AstraZeneca received upgrades to Buy, driven by strong pipeline prospects and revenue growth potential, with Roche's price target raised to CHF 338 and AstraZeneca's to £142.
UBS has named Roche as its preferred Swiss pharmaceutical stock, upgrading its rating to "Buy" and raising the target price from CHF 300 to CHF 338. The firm cites Roche's sustainable growth, driven by strong performances from Vabysmo and Ocrevus, and anticipates significant sales increases from ongoing development projects, including Ocrevus HD and Trontinemab. While Roche's earnings per share growth is projected at 8.1% from 2024 to 2029, slightly below the industry average, UBS remains optimistic about the company's long-term potential and cash flow for acquisitions.
UBS has downgraded Novartis shares from "Buy" to "Neutral," reducing the price target from 111 to 104 Swiss francs due to limited momentum in its research pipeline. Meanwhile, UBS shares saw a slight increase of 0.10 percent to CHF 30.22, but have declined by 4.17 percent over the past month, with a market capitalization of 110.6 billion euros. Investors are urged to consider their options in light of the latest analysis.
UBS has downgraded Novartis from "Buy" to "Neutral," significantly lowering its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's challenges, including numerous patent expiries and a lack of promising developments in the research pipeline, predicting underperformance through 2025. Novartis shares fell by 1.35% to CHF 96.48 following the announcement.
UBS has downgraded Novartis from "Buy" to "Neutral," reflecting a shift in its outlook for the pharmaceutical giant. The bank has also reduced its target price for Novartis shares from 111 to 104 Swiss francs, indicating a more cautious stance on the stock's performance.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reflecting a shift in its investment outlook. The bank has also reduced its target price for the pharmaceutical company from 111 to 104 Swiss francs.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in the research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in its research pipeline for 2025, favoring AstraZeneca as a better investment option.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs downgrades novartis while upgrading roche and astrazeneca ratings
British Pound Sterling
Swiss Franc
AstraZeneca PLC
Novartis AG
Hoffmann-La Roche AG
GBR
CHE
Show more
13:01 13.02.2025
ubs upgrades roche to preferred pharmaceutical stock with strong growth potential
United States Dollar
Euro
Swiss Franc
Nestlé S.A.
Sanofi
Hoffmann-La Roche AG
Novartis AG
CHE
Show more
12:00 13.02.2025
ubs downgrades novartis shares amid limited research momentum
11:00 13.02.2025
Novartis shares decline as UBS downgrades rating and price target
10:28 13.02.2025
ubs downgrades novartis share price and lowers target valuation
09:33 13.02.2025
UBS downgrades Novartis to neutral amid patent expiry concerns
09:05 13.02.2025
ubs downgrades novartis to neutral and lowers target price
08:14 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
UBS downgrades Novartis to neutral amid patent expiries and weak pipeline
Swiss Franc
Novartis AG
AstraZeneca PLC
CHE
Warren Buffett
Matthew Weston
Hubert Dichtl
Thomas Müller
Show more
07:46 13.02.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Central Bank Actions
Retail and Consumer Goods
CEO Changes
GDP Growth & Recession Forecasts
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Market Analysis and Predictions
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Domestic Politics
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
End Federal Reserve USD
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: